Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from a sell rating to a hold rating in a report released on Saturday.

Other equities research analysts have also recently issued research reports about the stock. Barclays increased their target price on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. JPMorgan Chase & Co. lowered their price objective on Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. UBS Group upped their target price on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research note on Monday, December 29th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Syndax Pharmaceuticals in a research note on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.20.

Syndax Pharmaceuticals Stock Performance

Shares of Syndax Pharmaceuticals stock opened at $21.19 on Friday. The company has a market capitalization of $1.84 billion, a PE ratio of -5.87 and a beta of 0.46. The company has a 50-day simple moving average of $20.72 and a two-hundred day simple moving average of $17.14. Syndax Pharmaceuticals has a one year low of $8.58 and a one year high of $22.73. The company has a debt-to-equity ratio of 2.78, a quick ratio of 4.42 and a current ratio of 4.64.

Insider Activity

In other news, CEO Michael A. Metzger sold 7,412 shares of the stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $20.62, for a total value of $152,835.44. Following the transaction, the chief executive officer directly owned 508,849 shares of the company’s stock, valued at approximately $10,492,466.38. This represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Keith A. Goldan sold 2,082 shares of the firm’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $20.62, for a total value of $42,930.84. Following the completion of the transaction, the chief financial officer owned 143,839 shares of the company’s stock, valued at approximately $2,965,960.18. The trade was a 1.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.10% of the stock is currently owned by insiders.

Institutional Trading of Syndax Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of SNDX. Larson Financial Group LLC increased its stake in shares of Syndax Pharmaceuticals by 192.2% in the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock worth $45,000 after acquiring an additional 1,922 shares during the period. Quantbot Technologies LP purchased a new stake in Syndax Pharmaceuticals in the third quarter valued at $53,000. Mirae Asset Global Investments Co. Ltd. grew its position in Syndax Pharmaceuticals by 26.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock worth $89,000 after purchasing an additional 893 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Syndax Pharmaceuticals during the 2nd quarter valued at about $66,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Syndax Pharmaceuticals by 103.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock valued at $79,000 after buying an additional 4,308 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.